Study to assess the effect of food and acid reducing agents on the absorption of Capivasertib in healthy participants

Exclusion Criteria

• - History of any clinically significant disease or disorder.
• - History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• - Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational medicinal product (IMP).
• - Any clinically significant abnormal findings in vital signs at screening and/or admission to the study center.
• -Clinically significant abnormalities in glucose metabolism defined by any of the following:
• (1) Diagnosis of diabetes mellitus type I or II (irrespective of management).
• (2) Blood glucose value ≥ 5.9 mmol/L after fasting for at least 8 hours, at screening or on admission to study center.
• (3) Glycosylated hemoglobin > upper limit of normal (up to 6.2% [44 mmol/mol]).
• - Any positive result on screening for serum hepatitis B surface antigen or antibody to hepatitis B core antigen, hepatitis C antibody, and human immunodeficiency virus antibody.
• - Known or suspected history of drug abuse.
• - Has received another new chemical entity within 3 months of the first administration of IMP in this study.
• - Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.
• - History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to capivasertib, rabeprazole, or famotidine.
• - Subjects who have previously received capivasertib.
• - Subject has a positive test result for Severe acute respiratory syndrome coronavirus 2 reverse transcription polymerase chain reaction on admission.
• - Subject has clinical signs and symptoms consistent with Coronavirus Disease 2019 (COVID-19) (eg, fever, dry cough, dyspnea, sore throat, anosmia/hyposmia, loss or reduced taste, and fatigue) or confirmed infection by appropriate laboratory test within the last 4 weeks prior to screening or on admission.
• - History of severe COVID-19 (hospitalization, extracorporeal membrane oxygenation, mechanically ventilated).
• - Subjects who are regularly exposed to the risk of COVID-19 infection as part of their daily life (eg, health care professionals working in COVID-19 wards or at emergency departments).
• - Subjects who have had a COVID-19 vaccine within 3 weeks prior to screening or are planning to get a COVID-19 vaccine during the study.